At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 324 enrolled
Drug / intervention
semaglutide +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes and Moderate Renal Impairment
In Brief
A Phase 3 clinical trial evaluating semaglutide and placebo for Diabetes and Diabetes Mellitus, Type 2. Completed, enrolled 324 participants across 117 sites in 8 countries.
Detailed Summary
This trial is conducted globally. The aim of this trial is to investigate efficacy and safety of oral semaglutide versus placebo in subjects with type 2 diabetes and moderate renal impairment.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes, Diabetes Mellitus, Type 2
CountriesDenmark, Finland, Israel, Poland, Russia, Sweden, United Kingdom, United States
Collaborators--
Timeline
Phase 3CompletedFinished
2017201820192020202120222023202420252026
First PostedJul 2016
Enrollment StartSep 2016
Primary CompletionApr 2018
Study CompletionMay 2018
TodayJul 2026
First PostedJul 11, 2016
Enrollment StartSep 20, 2016
Primary CompletionApr 10, 2018
Study CompletionMay 15, 2018
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 10.0 years ago
Interventions
semaglutidedrug
Oral administration once daily.
placebodrug
Oral administration once daily.